Patients with MRA treatment compared with patients with discontinued MRA treatment
| Charlson Comorbidity Index | Continued MRA (n=273) | Discontinued MRA (n=295) | P value |
| Myocardial infarction | 100 (37) | 125 (42) | 0.173 |
| Congestive heart failure | All | All | |
| Peripheral vascular disease | 11 (4) | 30 (10) | 0.005 |
| Cerebrovascular disease | 49 (18) | 85 (29) | 0.002 |
| Dementia | 16 (6) | 22 (7) | 0.440 |
| Chronic obstructive pulmonary disease | 29 (11) | 34 (11) | 0.732 |
| Connective tissue disease | 11 (4) | 21 (7) | 0.111 |
| Peptic ulcer disease | 10 (4) | 20 (7) | 0.097 |
| Diabetes mellitus—uncomplicated | 17 (6) | 12 (4) | 0.243 |
| Diabetes mellitus—end organ damage | 60 (22) | 71 (24) | 0.555 |
| Moderate to severe chronic kidney disease | 144 (52) | 203 (68) | <0.001 |
| Hemiplegia | 1 (0.4) | 1 (0.3) | 1.000 |
| Leukaemia/malignant lymphoma | 6 (2) | 16 (5) | 0.047 |
| Solid tumour/cancer | 31 (11) | 37 (13) | 0.663 |
| Metastatic disease | 3 (1) | 16 (5) | 0.004 |
| Liver disease—mild | 1 (0.4) | 3 (1) | 0.625 |
| Liver disease—moderate to severe | 3 (1) | 1 (0.3) | 0.355 |
| AIDS | 0 | 0 | |
| Total CCI score (n, SD) | 3.8 (1.9) | 4.8 (2.4) | <0.001 |
Values are means and SD or no. (%) when appropriate. P values are from the χ2, Student’s t-test or Fisher’s exact test as appropriate.
CCI, Charlson Comorbidity Index; MRA, mineralocorticoid receptor antagonist.